key: cord-0816798-7mdycixv
authors: Galloway, Ashley; Park, Yojin; Tanukonda, Vidisha; Ho, Yuk-Lam; Nguyen, Xuan-Mai T.; Maripuri, Monika; Dey, Andrew T.; Gerlovin, Hanna; Posner, Daniel; Lynch, Kristine E.; Cai, Tianxi; Luoh, Shiuh-Wen; Whitbourne, Stacey; Gagnon, David R.; Muralidhar, Sumitra; Tsao, Phillip S.; Casas, Juan P; Michael Gaziano, J.; Wilson, Peter WF; Hung, Adriana M; Cho, Kelly
title: Impact of COVID-19 Severity on Long-term Events in US Veterans using the Veterans Affairs Severity Index for COVID-19 (VASIC)
date: 2022-05-05
journal: J Infect Dis
DOI: 10.1093/infdis/jiac182
sha: 81d3003cf767eb4e40edd4786464d00304bd51c9
doc_id: 816798
cord_uid: 7mdycixv

In this retrospective cohort study of 94,595 SARS-CoV-2 positive cases, we developed and validated an algorithm to assess the association between COVID-19 severity and long-term complications (stroke, myocardial infarction, pulmonary embolism/deep vein thrombosis, heart failure, and mortality). COVID-19 severity was associated with a greater risk of experiencing a long-term complication days 31-120 post-infection. Most incident events occurred days 31-60 post-infection and diminished after day 91, except heart failure for severe patients and death for moderate patients, which peaked days 91-120. Understanding the differential impact of COVID-19 severity on long-term events provide insight into possible intervention modalities and critical prevention strategies.

Research has shown that adults infected with SARS-CoV-2 experience increased healthcare 2 utilization, cardiovascular complications, and greater risks of death, especially within the first 30 days 3 following infection [1] [2] [3] [4] [5] . Short-term risks (<30 days) for COVID-19 related cardiovascular events 4 have been well-documented, but evidence is still emerging on long-term risks (>30 days) [3] . 5

Understanding long-term clinical outcomes is especially critical when assessing COVID-19 prognosis 6

in Veterans, who have higher rates of cardiovascular disease compared to the general US population 7

[6]. Furthermore, quantification of COVID-19 severity and their impact on long-term events provides 8 new insight into clinical care and management. 9

The Clinical Progression Scale for COVID-19 (graded 1 to 10: uninfected to death) was developed by 10 the World Health Organization (WHO) to classify and standardize severity of COVID-19 disease [7] . 11

While correct identification of COVID-19 severity is critical in understanding prognosis of the 12 disease, the granularity of data required to correctly classify patients into the 10-point scale makes it 13 difficult for most clinicians or researchers to accurately use. Utilizing national electronic health record 14 (EHR) data from the Veterans Health Administration (VHA), we developed an adaptation of the WHO 15 scale to create a four-category VA Severity Index for COVID-19 (VASIC). VASIC was validated and 16 applied to a nationwide sample of SARS-CoV-2 positive Veterans' data to assess the association of 17 VASIC severity and long-term complications (stroke, myocardial infarction (MI), pulmonary 18 embolism (PE)/deep vein thrombosis (DVT), heart failure (HF), and mortality). VASIC can be readily 19 applied to EHR data to quantify COVID-19 disease severity and enables the standardization of clinical 20 decision-making for 30-day survivors. 21

We used VHA EHR data and Medicare and Medicaid services (CMS) data to create a national sample 23 of Veterans ≥18 years of age who were both classified as a confirmed positive case by the VA 24

National Surveillance Tool (NST), and had a positive SARS-CoV-2 PCR lab result within the VHA 25 between March 1, 2020-December 31, 2020 [8] . Infection date was defined as the first positive PCR 26

result in the VA. Cases were classified according to the highest VASIC status experienced by day 30 1 post-infection, and long-term complications were assessed days 31-120 post-infection. For 2 comparison, we included a control group consisting of patients with a negative SARS-CoV-2 PCR 3 test, who were admitted with pneumonia diagnosis within the same timeframe as the cases. 4

The VASIC algorithm, was created by summarizing the 10-point WHO Scale into 4 categories: mild 5 (WHO scores 1-3), moderate (4-5), severe (6-9), and most severe (10) [7] . All VASIC categories 6 required the same definition -a positive PCR and satisfied of one of the following criteria: mild (not 7 hospitalized or hospitalized for ≤24 hours); moderate (hospitalized for > 24 hours, with or without low 8 flow oxygen therapy); severe (hospitalized for > 24 hours with high flow oxygen therapy, intubation, 9 mechanical ventilation, vasopressors, Endothelial Corporeal Membrane Oxygenation (ECMO) or 10 kidney dialysis); and most severe (dead). Data for all categories was ascertained from EHR procedure 11 codes between days 0-30 post-infection. COVID-19 related hospitalizations were attributed to patients 12 who were hospitalized -7 days to +30 days relative to the date of their first positive PCR test. COVID-19 severity on monthly incidence rates, with a separate model for each event. 25

This study was reviewed and approved by the institutional review boards of Emory University (IRB# 1 389) and VA Boston Healthcare System (IRB# 3310-X). This study was restricted to secondary data 2 analysis, and thus, the requirement for informed consent from participants was waived. This 3 manuscript follows the 4

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline 5 for cohort studies. 6

Results 7

Among the 94,595 SARS-CoV-2 positive Veterans, VASIC classified 72,253 as mild, 13,815 8 moderate, and 4,394 severe, and identified 4,133 most severe. The median age of those infected was 9 60 years, with 87% male, 63.2% White, and 24.4% Black (Supplementary Table 1 approximately 10% of patients as moderate who had clinically mild symptoms but were hospitalized 15 for >24 hours due to reasons unrelated to COVID-19. 16

A summary of incident events by VASIC category is shown in Table 1 . The incident rates for 17 complications by VASIC (mild, moderate and severe, respectively) from day 31-120 were: stroke 18 (0.2%, 0.7%, and 1.1%); MI (0.2%, 0.7%, 1.0%); PE/DVT (0.2%,0.6%,1.5%); HF (0.2%, 1.1%, 19 2.1%); death (0.6%, 5.2%,9.4%). Severe patients had the highest rates of incident events, followed by 20 moderate then mild. While the risks of incident events decrease for moderate and severe patients 21 9.4%. The median lengths of hospitalization for the moderate and severe patients were 5 days 16 (IQR=8) and 15 days (IQR=20), respectively. 17

The VASIC algorithm was developed and validated on the largest single national EHR database to 19 examine long-term outcomes of COVID-19. It can be applied to other EHR databases for which 20 SARS-CoV-2 PCR lab tests are available. Our results illustrate that patients experience long-term 21 complications beyond 4 weeks post-infection, and that incidence of these events increase by COVID- VASIC can be incorporated into genetic studies and EHR trial emulation analyses, using severity 7 status as an endpoint to identify novel treatments against COVID-19, and to evaluate efficacy and 8 safety of COVID-19 vaccines. Delineating cases that present as clinically mild/asymptomatic but are 9 hospitalized for concerns unrelated to COVID-19 continues to be a challenge for EHR algorithms. 10 Future work will also include further examination of factors that contribute to a patient's prognosis 11 such as biomarkers of severe disease and continued investigation of progression of COVID-19. 12

This study was supported using data from the VA COVID-19 Shared Data Resource. The views and 14 opinions expressed in this manuscript do not represent those of the Department of Veterans Affairs or 15 the United States 16

Government. 17

The authors declare no conflicts of interest related to this research. 

High-dimensional characterization of post-acute sequelae of 2 COVID-19

COVID-19 and the heart: An 4 update for clinicians

Risk 6 of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-7 controlled case series and matched cohort study

Incidence of thrombotic complications in 9 critically ill ICU patients with COVID-19

6-month neurological and 11 psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using 12 electronic health records

Veterans and risk of heart disease in the United States: a cohort with 20 years of 14 follow up

Characterisation WHOWGotC, Management of C-i. A minimal common outcome measure 16 set for COVID-19 clinical research

A Natural Language 18 Processing System for National COVID-19 Surveillance in the US Department of Veterans 19

Association for Computational Linguistics

The measurement of observer agreement for categorical data

Long-term cardiovascular outcomes of COVID-19

Abbreviations: MI, myocardial infarction; PE